Clinical Trials Browser

Phase 1/2 × INDUSTRY × mirvetuximab soravtansine × Clear all

NCT06390995 2025-06-15

A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

Phase 1/2 Active not recruiting

Ovarian Neoplasms

NCT02606305 2024-06-14

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1/2 Completed

264 enrolled 41 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms